Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 8/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.45 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.45 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 2/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.44 |
| ▸ | KDM1A | O60341 | 3/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.43 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23680462 | 0.90 | CTSL (0.45) | SIRT2SIRT1SIRT3SIRT5CTSL | |
| SCHEMBL23286081 | 0.90 | SSTR3 (0.53) | SIRT2SIRT1SIRT3SIRT5KDM1A | |
| SCHEMBL16847664 | 0.87 | SIRT5 (0.54) | SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL16847661 | 0.87 | SIRT5 (0.54) | SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL23286132 | 0.86 | HDAC8 (0.52) | CTSL | |
| SCHEMBL23286090 | 0.86 | HTT (0.41) | SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL23286080 | 0.84 | PTPN1 (0.45) | SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL30527290 | 0.83 | SIRT5 (0.62) | SIRT2SIRT1SIRT3SIRT5F2 | |
| SCHEMBL25932816 | 0.83 | SIRT5 (0.62) | SIRT2SIRT1SIRT3SIRT5F2 | |
| SCHEMBL16450347 | 0.83 | PTPN1 (0.48) | SIRT5KDM1AMAOAKDM1BRCOR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230128167-A1 | OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREOF | MABPLEX INTERNATIONAL, LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20210230218-A1 | OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREOF | MABPLEX INTERNATIONAL, LTD. (CN) | 2021-07-29 | — | — | US | disclosed |
| EP-3838913-A1 | OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREFOR | MabPlex International Co., Ltd. (CN) | 2021-06-23 | — | — | EP | disclosed |
| WO-2021077317-A1 | OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREFOR | 烟台迈百瑞国际生物医药股份有限公司 | 2021-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128167-A1 | OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREOF | VIP, DNPEP, PREP | SIRT2 3512/4885SIRT1 2709/4885SIRT3 3528/4885 |
| US-20210230218-A1 | OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREOF | VIP, DNPEP, PREP | SIRT2 3512/4885SIRT1 2709/4885SIRT3 3528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.